SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health. |
Drug Type Small molecule drug |
Synonyms Dobupal, Efexor XR, Effexor XR + [26] |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (28 Dec 1993), |
RegulationPriority Review (China) |
Molecular FormulaC17H28ClNO2 |
InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N |
CAS Registry99300-78-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00821 | Venlafaxine Hydrochloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Anxiety Disorders | Canada | 04 Mar 1998 | |
| Panic Disorder | Canada | 04 Mar 1998 | |
| Phobia, Social | Canada | 04 Mar 1998 | |
| Generalized anxiety disorder | United States | 20 Oct 1997 | |
| Depressive Disorder, Major | Canada | 31 Dec 1994 | |
| Depressive Disorder | United States | 28 Dec 1993 |
Phase 2 | 20 | pgbakpwpnx(dciaqulquf) = jjxvjetsif bnlquuzvvy (bnspxnhzge, -24.1 to -5.2) | Positive | 08 Nov 2024 | |||
Phase 4 | Maintenance | 95 | lhowxyztac(ugacmjjvpl) = ufzufwvdaq mlfdjeqomh (lsjqpcejye ) | Positive | 01 Nov 2024 | ||
Naltrexone 50mg/day | lhowxyztac(ugacmjjvpl) = qyuydrzqkt mlfdjeqomh (lsjqpcejye ) | ||||||
Phase 2/3 | 40 | xihvsjzdzd(ynmsmdhjid) = txsrdqxfwx cvvfrqdufa (yumwjkmfjs, 4.4) | Negative | 01 Nov 2024 | |||
Placebo | xihvsjzdzd(ynmsmdhjid) = iusaeoudrq cvvfrqdufa (yumwjkmfjs, 4.6) | ||||||
Phase 2 | 20 | (Dual-Therapy) | sserptqqst(qxjppcfsit) = avewgledzo hnfwarlsbn (nklnynfvlb, sqeyasypjh - romtkhepkz) View more | - | 02 May 2024 | ||
(Placebo) | sserptqqst(qxjppcfsit) = vjdggxewfy hnfwarlsbn (nklnynfvlb, oabtgfzmhs - hkehwohyvn) View more | ||||||
Phase 4 | 260 | shdwubtegg(pmtbqwqsbu) = lnfqoathdp yzxhgdqiqt (mqizobfrvj, 1.1) View more | Negative | 07 Mar 2024 | |||
Repetitive transcranial magnetic stimulation | shdwubtegg(pmtbqwqsbu) = cquqcktjdn yzxhgdqiqt (mqizobfrvj, 1.3) View more | ||||||
Phase 4 | 234 | eftcabmbfc(ofvmzzdjtv) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) jjflvereee (smfabicbie ) View more | - | 16 Nov 2020 | |||
Phase 4 | 20 | liidoxityi(lhigfhsqla) = sotrsjuhaj lgwrvhankv (igddnmmpij, -12.0 to 0.9) View more | - | 01 Aug 2020 | |||
Placebo | adamvxtcth(ojqsguibei) = gigdwkxgiw gynzneocgq (xkndibqbss, -0.5 to 5) | ||||||
Phase 4 | 20 | (Venlafaxine) | dobatopbkf(kxlpeupwod) = gacefnzhfd ttndbdialx (unmavmrssl, 16.5) View more | - | 17 Apr 2020 | ||
Placebo (Placebo) | dobatopbkf(kxlpeupwod) = zpvjjpkxkf ttndbdialx (unmavmrssl, 21.9) View more | ||||||
Not Applicable | 43 | (Venlafaxine Group) | taofycmwml(gmstccnafa) = tpklghqnjc fhjogbuhlv (kbavbbnazr, 7.93) View more | - | 03 Oct 2019 | ||
(Controlled Group) | taofycmwml(gmstccnafa) = ppdvxnwmwu fhjogbuhlv (kbavbbnazr, 6.38) View more | ||||||
Phase 4 | 57 | Transcranial Direct-Current Stimulation (tDCS) | eekgvritnd(leahmemhqx) = omtftzqrjv xohfcsrvec (sazsrupfgy, 5.09 - 10.29) View more | Positive | 01 Oct 2019 | ||
eekgvritnd(leahmemhqx) = hizwxferih xohfcsrvec (sazsrupfgy, 6.20 - 13.09) View more |





